Literature DB >> 8151775

Equine infectious anemia virus trans-regulatory protein Rev controls viral mRNA stability, accumulation, and alternative splicing.

L Martarano1, R Stephens, N Rice, D Derse.   

Abstract

The cis- and trans-acting components of the Rev regulatory pathway employed by equine infectious anemia virus (EIAV) to regulate and coordinate viral gene expression were examined in complementation experiments. Viral protein expression and mRNA expression were compared in cells transiently transfected with wild-type or mutant proviruses in combination with Rev expression plasmids. Mutation of the predicted rev gene abolished Gag protein synthesis, and this defect was complemented, in trans, by Rev. Analysis of viral mRNAs from transfected cells confirmed that EIAV expresses five major mRNAs: the full-length and singly spliced mRNAs contain introns and encode viral structural proteins while the three fully spliced mRNAs, encoding nonstructural genes, are generated by alternative splicing. Compared to cells transfected with the wild-type provirus, the intron-containing mRNAs produced from the rev-minus mutant were present at reduced levels in the nuclear RNA fraction and were not detected in the cytoplasm. This pattern of viral mRNA synthesis was restored to the wild-type pattern by providing Rev in trans. In contrast to the intron-containing mRNAs, cytoplasmic accumulation of the multiply spliced class of mRNAs was independent of Rev. Closer examination of the multiply spliced class of viral mRNAs by reverse transcriptase-PCR analysis revealed a Rev-dependent alternative splicing phenomenon. In the absence of Rev, proviruses expressed a four-exon mRNA at high levels; the addition of Rev caused both a decrease in the levels of the four-exon mRNA and the appearance of a related mRNA lacking exon 3. The cis-acting RNA elements that mediate Rev responsiveness were studied with deleted proviruses, which revealed that EIAV contains at least two elements located near the ends of envelope gene. Unlike the Rev-responsive elements in other retroviruses, the cis-acting regions of EIAV do not appear to form complex secondary structures.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8151775      PMCID: PMC236800     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  74 in total

1.  Oligomerization and RNA binding domains of the type 1 human immunodeficiency virus Rev protein: a dual function for an arginine-rich binding motif.

Authors:  M L Zapp; T J Hope; T G Parslow; M R Green
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

2.  cis- and trans-acting regulation of gene expression of equine infectious anemia virus.

Authors:  P L Dorn; D Derse
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

Review 3.  The lentiviruses: maedi/visna, caprine arthritis-encephalitis, and equine infectious anemia.

Authors:  W P Cheevers; T C McGuire
Journal:  Adv Virus Res       Date:  1988       Impact factor: 9.937

4.  Phosphorylation of the rev gene product of human immunodeficiency virus type 1.

Authors:  J Hauber; M Bouvier; M H Malim; B R Cullen
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

5.  Two cis-acting elements responsible for posttranscriptional trans-regulation of gene expression of human T-cell leukemia virus type I.

Authors:  M Seiki; J Inoue; M Hidaka; M Yoshida
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

6.  Immunofluorescent localization of equine infectious anemia virus in tissue.

Authors:  T C McGuire; T B Crawford; J B Henson
Journal:  Am J Pathol       Date:  1971-02       Impact factor: 4.307

7.  Subcellular localization of the human immunodeficiency virus trans-acting art gene product.

Authors:  B R Cullen; J Hauber; K Campbell; J G Sodroski; W A Haseltine; C A Rosen
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

8.  Antigenic variation during persistent infection by equine infectious anemia virus, a retrovirus.

Authors:  R C Montelaro; B Parekh; A Orrego; C J Issel
Journal:  J Biol Chem       Date:  1984-08-25       Impact factor: 5.157

Review 9.  Equine infectious anemia virus: immunopathogenesis and persistence.

Authors:  W P Cheevers; T C McGuire
Journal:  Rev Infect Dis       Date:  1985 Jan-Feb

10.  Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes.

Authors:  M H Malim; J Hauber; R Fenrick; B R Cullen
Journal:  Nature       Date:  1988-09-08       Impact factor: 49.962

View more
  23 in total

1.  Gag localization and virus-like particle release mediated by the matrix domain of human T-lymphotropic virus type 1 Gag are less dependent on phosphatidylinositol-(4,5)-bisphosphate than those mediated by the matrix domain of HIV-1 Gag.

Authors:  Jingga Inlora; Vineela Chukkapalli; David Derse; Akira Ono
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

2.  Differential requirements for alternative splicing and nuclear export functions of equine infectious anemia virus Rev protein.

Authors:  M E Harris; R R Gontarek; D Derse; T J Hope
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

3.  Biological characterization of Rev variation in equine infectious anemia virus.

Authors:  M Belshan; M E Harris; A E Shoemaker; T J Hope; S Carpenter
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Binding of equine infectious anemia virus rev to an exon splicing enhancer mediates alternative splicing and nuclear export of viral mRNAs.

Authors:  M Belshan; G S Park; P Bilodeau; C M Stoltzfus; S Carpenter
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

5.  Equine viperin restricts equine infectious anemia virus replication by inhibiting the production and/or release of viral Gag, Env, and receptor via distortion of the endoplasmic reticulum.

Authors:  Yan-Dong Tang; Lei Na; Chun-Hui Zhu; Nan Shen; Fei Yang; Xian-Qiu Fu; Yu-Hong Wang; Li-Hua Fu; Jia-Yi Wang; Yue-Zhi Lin; Xue-Feng Wang; Xiaojun Wang; Jian-Hua Zhou; Cheng-Yao Li
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

6.  Interactions among SR proteins, an exonic splicing enhancer, and a lentivirus Rev protein regulate alternative splicing.

Authors:  R R Gontarek; D Derse
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

7.  Unique evolution characteristics of the envelope protein of EIAV(LN₄₀), a virulent strain of equine infectious anemia virus.

Authors:  Xuefeng Wang; Shuai Wang; Yuezhi Lin; Chenggang Jiang; Jian Ma; Liping Zhao; Xiaoling Lv; Fenglong Wang; Rongxian Shen; Jianhua Zhou
Journal:  Virus Genes       Date:  2011-01-08       Impact factor: 2.332

8.  Replication in vitro and in vivo of an equine infectious anemia virus mutant deficient in dUTPase activity.

Authors:  D L Lichtenstein; K E Rushlow; R F Cook; M L Raabe; C J Swardson; G J Kociba; C J Issel; R C Montelaro
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

9.  Inhibitory activity of the equine infectious anemia virus major 5' splice site in the absence of Rev.

Authors:  W Tan; M Schalling; C Zhao; M Luukkonen; M Nilsson; E M Fenyö; G N Pavlakis; S Schwartz
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Leptomycin B inhibits equine infectious anemia virus Rev and feline immunodeficiency virus rev function but not the function of the hepatitis B virus posttranscriptional regulatory element.

Authors:  G C Otero; M E Harris; J E Donello; T J Hope
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.